Signal Genetics, Inc. Announces Closing of Initial Public Offering of 850,000 Shares of Common Stock

        Print
| Source: Signal Genetics, Inc.

NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the closing of its previously announced initial public offering of 850,000 shares of its common stock at a price to the public of $10.00 per share. Gross proceeds raised by Signal in the offering were $8,500,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Signal has granted the underwriters a 45-day option to purchase up to 127,500 additional shares of common stock to cover over-allotments, if any.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 17, 2014.

The offering was made by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, email: prospectus@aegiscap.com. Investors may also obtain these documents at no cost by visiting the Securities and Exchange Commission's website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Signal Genetics, Inc.

Signal Genetics, Inc., headquartered in New York, New York, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Our mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. We were founded in January 2010 and became the exclusive licensee in our licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, or UAMS, in April 2010.

The Ruth Group
David Burke
Tel: 646-536-7009